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Abstract: Traditional risk factors and environmental exposures only explain less than half of the
disease burden. The developmental origin of the health and disease (DOHaD) concept proposes that
prenatal and early postnatal exposures increase disease susceptibility throughout life. The aim of this
work is to demonstrate the application of the DOHaD concept in a chained risk assessment and to
provide an estimate of later in life burden of disease related to maternal smoking. We conducted three
systematic literature searches for meta-analysis and reviewed the literature reporting meta-analyses of
long-term health outcomes associated with maternal smoking and intermediate risk factors (preterm
birth, low birth weight, childhood overweight). In the chained model the three selected risk factors
explained an additional 2% (34,000 DALY) of the total non-communicable disease burden (1.4 million
DALY) in 2017. Being overweight in childhood was the most important risk factor (28,000 DALY).
Maternal smoking was directly associated with 170 DALY and indirectly via the three intermediate
risk factors 1000 DALY (1200 DALY in total). The results confirm the potential to explain a previously
unattributed part of the non-communicable diseases by the DOHAD concept. It is likely that relevant
outcomes are missing, resulting in an underestimation of disease burden.
Keywords: Burden of disease; chained risk assessment; developmental origin of health and
disease (DOHaD); smoking; pregnancy; low birth weight; preterm birth; overweight, systematic
literature review
1. Introduction
Over the last decades the prevalence of chronic diseases has been increasing. In Finland, about
1.6 million healthy years of life were lost in 2017 due to morbidity and premature mortality [1]. The
majority (86%) of this burden was due to non-communicable diseases, while infectious diseases
accounted only for 4% [2]. Therefore it is important for the prevention of chronic diseases to identify
risk factors. The recent Global Burden of Disease study (GBD2017) analyzed a wide set of risk factors
and was able to explain 44% of non-communicable disease burden in Finland in 2017 [2].
The complexity of disease etiology and poorly understood exposure interactions contribute to the
lack of understanding of risk factors for disease [3]. The causal risk chain may include a number of
independent risk factor or exposure, intermediate states that mediate the effect of the initial exposure
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onto the outcome and modifying factors that may interact with any factor in the risk chain. Latency
times between the initial exposure, intermediate states and the outcome can span from the prenatal
phase to decades into adult life (Figure 1) [4]. The above mentioned GBD2017 prevalence-based
estimates are mostly cross-sectional, linking directly the exposures for a given target year with the
corresponding outcomes. This approach to large extent omits the latency times.
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Already in the 1970 and 80s, significant associations between early conditions and health, 
disease, and mortality in later life were reported (e.g., [5–8]) leading to the developmental origin of 
health and disease (DOHaD) concept. Effects of early exposures during critical windows of 
development can be persistent and may result in health consequences later in life [9–11]. The 
development of tissues and organ systems during fetal and early postnatal life makes this period 
especially susceptible for exposure to chemical, physical, and nutritional stress factors. Prenatal short-
term, adverse health effects in the fetus can be caused by maternal exposure to environmental 
chemicals even at doses clearly below the no-effect levels in adults [12]. While early exposure may 
have adverse long-term consequences, the high developmental plasticity can compensate challenges. 
The compensation is possible since one genotype can give rise to a range of different physiological or 
morphological states in response to different environmental conditions during development [5]. With 
increasing age and the accumulation of risks, the plasticity of the response to challenges decreases 
and the risk for inadequate responses to new challenge increases potentially resulting in disease onset 
[13].  
Prenatal maternal smoking is a known early exposure associated with adverse birth outcomes 
[14,15]. Despite public health efforts, maternal smoking remains to be prevalent with 14% of all 
newborns exposed in Finland in 2015 [16]. Exposure to maternal smoking leads to epigenetic changes 
in the exposed fetus [16–19], indicating persistent changes in susceptibility to environmental 
exposures [5]. Emerging evidence is suggesting DNA methylation as a mechanism for the effect of 
maternal smoking on birth weight [20]. Furthermore, maternal smoking during early pregnancy is 
causing disproportionate growth restriction, demonstrating differences in susceptibility of organ 
systems for adverse effects [15]. Growth restriction is evident as early as during the first trimester 
ultrasound scans [21]. Growth restriction after early exposures is likely attributable to disturbances 
during organogenesis potentially with persistent effects. Low birth weight (LBW) and preterm birth 
(PTB) are independent risk factors for later life disease as already demonstrated in the 1980s [6,22,23] 
and evidence is growing for epigenetic changes associated with these risk factors [24]. Low birth 
weight and PTB are the most prominent adverse health effects of maternal smoking with 
epidemiological evidence reaching back to the 1950s [25,26]. Thus maternal smoking is not only 
causing direct adverse health effects, it also interferes with normal response to environmental 
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Figure 1. Causal models for disease etiology describing interactions between risk factors and the
outcomes (modified from [5]). The outcomes can be immediate, or occur later in the life. A, B, C as
generic placeholders for risk factors and outcomes in the causal models.
Already in the 1970 and 80s, significant associations between early conditions and health, disease,
and mortality in later life were reported (e.g., [5–8]) leading to the developmental origin of health and
disease (DOHaD) concept. Effects of early exposures during critical windows of development can
be persistent and may result in health consequences later in life [9–11]. The development of tissues
and organ systems during fetal and early postnatal life makes this period especially susceptible for
exposure to chemical, physical, and nutritional stress factors. Prenatal short-term, adverse health
effects in the fetus can be caused by maternal exposure to environmental chemicals even at doses
clearly below the no-effect levels in adults [12]. While early exposure may have adverse long-term
consequences, the high developmental plasticity can compensate challenges. The compensation is
possible since one genotype can give rise to a range of different physiological or morphological states
in response to different environmental conditions during development [5]. With increasing age and the
accumulation of risks, the plasticity of the response to challenges decreases and the risk for inadequate
responses to new challenge increases potentially resulting in disease onset [13].
Prenatal maternal smoking is a known early exposure associated with adverse birth
outcomes [14,15]. Despite public health efforts, maternal smoking remains to be prevalent with
14% of all newborns exposed in Finland in 2015 [16]. Exposure to maternal smoking leads to epigenetic
changes in the exposed fetus [16–19], indicating persistent changes in susceptibility to environmental
exposures [5]. Emerging evidence is suggesting DNA methylation as a mechanism for the effect of
maternal smoking on birth weight [20]. Furthermore, maternal smoking during early pregnancy
is causing disproportionate growth restriction, demonstrating differences in susceptibility of organ
systems for adverse effects [15]. Growth restriction is evident as early as during the first trimester
ultrasound scans [21]. Growth restriction after early exposures is likely attributable to disturbances
during organogenesis potentially with persistent effects. Low birth weight (LBW) and preterm birth
(PTB) are independent risk factors for later life disease as already demonstrated in the 1980s [6,22,23]
and evidence is growing for epigenetic changes associated with these risk factors [24]. Low birth weight
and PTB are the most prominent adverse health effects of maternal smoking with epidemiological
evidence reaching back to the 1950s [25,26]. Thus maternal smoking is not only causing direct adverse
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health effects, it also interferes with normal response to environmental challenges increasing the
susceptibility for disease. In order to evaluate total health consequences of maternal smoking, these
changes in susceptibility should be taken into account as part of the risk chain in disease etiology.
The aim of this work is to demonstrate the application of the DOHaD concept using maternal
smoking as exposure. Specifically to provide chained health risk estimates mediated via selected
intermediate risk factors we want to (i) identify relevant health end points in later life; (ii) obtain
quantitative estimates for the associations; and (iii) calculate direct and indirect chained population
attributable fractions and burden estimates.
2. Materials and Methods
Overall, we applied a chained approach to assess health impacts associated with maternal smoking
via intermediate risk factors (Figure 2). Three literature reviews were conducted to identify the health
effects associated with maternal smoking and the included three intermediate risk factors that have
previously been associated with maternal smoking: preterm birth (PTB), low birth weight (LBW),
and childhood overweight and obesity.
Attributable burden of disease was quantified in five groups: first, the direct disease burden
associated with maternal smoking, then the burden attributable to the three intermediate risk factors
and lastly the fraction of disease burden associated with the three intermediate risk factors that can be
indirectly attributed to maternal smoking.
Int. J. Environ. Res. Public Health 2020, 17, 1472 3 of 17 
 
ch llenges increasing th  susceptibility for dis ase. In order to evaluate total health co seque ces of 
mat rnal smoking, these chang s in susceptibility should be taken into account s part of the ri k 
c ain in di eas  etiology.  
 ai  of this ork is to de onstrate the application of the DO a  concept using aternal 
s i  as expos re. ifi ll  t  i  i  lt  ri  esti t  e i t  via selecte  
i ter i t  i  f t   t t  (i) i e tif  rele t e lt  e  oi ts i  later life; (ii) obtai  
quantitati e esti t  f r t e associati s; a  (iii) calc late irect an  indirect chaine  populatio  
attrib table fractions and burden esti ates. 
2. Materials and Methods  
Overall, we applied a chained approach to assess health impacts associated with maternal 
smoking via intermediate risk factors (Figure 2). Three literature reviews were conducted to identify 
the health effects associated with maternal smoking and the included three intermediate risk factors 
that have previously been associated with maternal smoking: preterm birth (PTB), low birth weight 
(LBW), and childhood overweight and obesity.  
Attributable burden of disease was quantified in five groups: first, the direct disease burden 
associated with maternal smoking, then the burden attributable to the three intermediate risk factors 
and lastly the fraction of disease burden associated with the three intermediate risk factors that can 
be indirectly attributed to maternal smoking.  
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2.1. Identification of Relevant Health Endpoints 
The literature reviews with pre-defined inclusion/exclusion criteria were conducted in PubMed 
(R1–R3 in Figure 2). The searches were limited to meta-analyses to ensure a certain degree of evidence 
for the association with later life adverse effects. In detail, the inclusion criteria were: 
• Meta-analysis with statistically significant pooled risk estimate; 
• Background disease burden of reported endpoint is available; 
• Free full text is available in English. 
The literature search was not restricted in respect to publication year. The searches were 
conducted in October (Preterm birth and low birth weight, maternal smoking) and November 
(Childhood overweight and obesity) 2018. 
From the initially identified 3766 article,s 27 were finally included (Figure 3). The detailed 
literature search is documented in supplementary material. Relative risk (RR), hazard ratio (HR), or 
odds ratio (OR) were accepted as risk estimate. If more than one meta-analysis was available for the 
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Figure 2. Design of the chained risk model for maternal smoking. Review 1 (R1) identifies later life
health outcomes associated directly with maternal smoking and reviews 2–3 (R2, R3) those mediated
via the three intermediate factors.
2.1. Identification of Relevant Health Endpoints
The literature reviews with pre-defined inclusion/exclusion criteria were conducted in PubMed
(R1–R3 in Figure 2). The searches were limited to meta-analyses to ensure a certain degree of evidence
for the association with later life adverse effects. In detail, the inclusion criteria were:
• Meta-analysis with statistically significant pooled risk estimate;
• Background disease burden of reported endpoint is available;
• Free full text is available in English.
The literature search was not restricted in respect to publication year. The searches were conducted
in October (Preterm birth and low birth weight, maternal smoking) and November (Childhood
overweight and obesity) 2018.
From the initially identified 3766 articles 27 were finally included (Figure 3). The detailed literature
search is documented in supplementary material. Relative risk (RR), hazard ratio (HR), or odds
ratio (OR) were accepted as risk estimate. If more than one meta-analysis was available for the same
Int. J. Environ. Res. Public Health 2020, 17, 1472 4 of 17
endpoint, the newest and largest one was used. Used estimates are listed in Table S1. The risk estimates
identified in the systematic literature reviews were used in the estimation of the population attributable
fraction, denoted as RRk,j in Equation (2). A summary of the included studies and risk estimates is
listed in Table S1 in the supplemental material.
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In a chained assessment the indirect impact of maternal smoking mediated via the three selected
intermediate risk factors was quantified. The contribution of maternal smoking to disease burden
attributable to the intermediate risk factors (ABi) was estimated using PAF approach and the disease
burden attributable to each intermediate risk factor (Equation (3)). PAF is calculated as in Equation (2)






PAFk, j ∗ AB j
)
(3)
The MATEX cohort was used for exposure data [16]. In Finland in 2016, about 6.8% of newborns
were exposed to smoking only during the fist trimester and additional 7.0% were exposed to maternal
smoking also after the 1st trimester (Table 1). Statistically significant association for smoking during
early pregnancy was reported only for low birth weight. For preterm birth and childhood overweight
and obesity only smoking throughout pregnancy was considered a relevant exposure.
The prevalence of PTB and LBW with corresponding risk estimates for the associations with
maternal smoking were identified from the MATEX birth cohort [15]. The prevalence of childhood
overweight and obesity were estimated from Finnish population growth curves based on the WHO
definition of overweight and obesity (Table 1) [28]. PAF for LBW and PTB have been separately
calculated for smoking only during early pregnancy and smoking in late pregnancy to take into account
differences in risk estimates.
Table 1. Risk factor definition and population attributable fraction (PAF) estimation for the association
















2500 g BMI ≥ 25 at BMI ≥ 30
Exposure
only during 1st trimester
throughout pregnancy
6.8 % a [16]









Risk estimate (RR) 1.38 [15] 1.11
a [15]
2.22 b [15] 1.37 [29] 1.55 [29]
Population attributable
fraction










n/a no statistically significant association, a Estimate for smoking only during 1st trimester, b Estimate smoking:
smoking throughout pregnancy.
3. Results
Three reviews were conducted to identify relevant endpoints and risk estimates to quantify
disease burden associated with maternal smoking and intermediate risk factors in a chained risk model.
In total, 27 meta-analyses were identified as eligible, resulting in 24 diseases to be included in the
risk estimation (Table 2). The health outcomes included cancer, cardiovascular diseases, mental and
cognitive diseases, diabetes, asthma, congenital anomalies, and chronic kidney disease.
The ORs identified in the systematic literature reviews ranged from 1.09 (95% CI 1.02–1.17) for the
association of PTB with acute leukemia and maternal smoking with nervous system cancers, to 5.6
(95% CI 2.34–13.3) for childhood obesity with diabetes later in life. The only other ORs above 2 were for
PTB and attention deficit/hyperactivity disorder (OR 2.6, 95% CI 1.85–3.78), childhood overweight and
diabetes (OR 2.4, 95% CI 1.54–3.75), and PTB and intellectual disability (OR 2.03, 95% CI 1.79–2.31) (see
the supplementary Table S1). The average population attributable fraction was 2.5% with individual
PAFs ranging between 0.4% (PTB and depression, LBW and depression, PTB and acute leukemia) and
16% (childhood overweight and diabetes) (see the supplementary material Table S2).
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The overall burden of non-communicable diseases in Finland in 2017 was 1.4 million DALY [2].
The disease burden attributable to endpoints associated with maternal smoking or intermediate risk
factors included in this work was about 380,000DALY (28% of the total non-communicable disease
burden) (Table 2). Cardiovascular disease burden (242,000 DALY) was the main contributing factor to
the included burden, followed by diabetes (56,000 DALY) and cancer (44,000 DALY). Depression was
the smallest contributor to the total disease burden with about 300 DALY.
Table 2. Summary of identified endpoints in three umbrella systematic literature reviews and



















1.1 Acute leukemia <20years 806 3.9 6.8 n/a 32 43
1.2 Lymphoma <20years 238 7 n/a n/a n/a 7
1.3 Nervous system cancer <20years 832 5.2 n/a n/a n/a 5.2
1.4 Testicular cancer <20years 11 n/a n/a 0.22 n/a 0.22
1.5 Wilms’ tumor <20years 95 n/a 1.6 n/a n/a 1.6
1.6 Other cancer a ≥20years 41,647 n/a n/a n/a 2570 2570
2 Cardiovascular
2.1 Coronary heart disease All ages 157,588 n/a n/a 2066 3184 5250
2.2 Essential hypertension All ages 12,532 n/a 153 n/a 1323 1477
2.3 Stroke All ages 71,952 n/a n/a n/a 5088 5088
3 Mental & cognitivedisorders
3.1 Depression ≥20years 292 n/a n/a 2.6 3.5 6.1





All ages 703 n/a 43 n/a 4.2 47
3.4 Intellectual disability All ages 1059 n/a 42 n/a n/a 42
4 Other groups
4.1 Diabetes All ages 55,898 n/a 1059 977 15,987 18,023
4.2 Asthma All ages 13,809 39 14 189 47 290
4.3 Congenital anomalies b All ages 8593 115 n/a n/a n/a 115
4.4 Chronic kidney disease All ages 11,807 n/a n/a 506 n/a 506
Sum 382,388 170 1376 3909 28,241 33,696
Indirectly attributable to
maternal smoking 170 35 167 839 1211
Indirectly attributable to
maternal smoking (%) 3 % 4 % 3 % 4 %
n/a: no statistically significant association identified. a Including esophageal adenocarcinoma, liver cancer, multiple
myeloma, pancreatic cancer, thyroid cancer. b Including the following congenital anomalies: heart anomalies,
orofacial clefts, digestive anomalies, musculoskeletal anomalies.
Out of 1.4 million DALY caused by non-communicable diseases, about 33,500 DALY could
be directly attributed to intermediate risk factors included in this work. Childhood overweight
was associated with the greatest health impact (28,000 DALY), followed by LBW (4000 DALY),
PTB (1400 DALY), and the direct impact of maternal smoking (170 DALY) (Table 2; Figure 4).
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Figure 4. Bubble plot indicating the total burden of disease in Finland in light blue (2017) with the
attributable fractions due to risk factors included in the Global Burden of Disease Study (blue), and
maternal smoking (direct burden in pink, indirect burden in dark red) and intermediate risk factors
considered in this work (green shades). Based on data from [2].
The contribution of maternal smoking to the disease burden of the three intermediate risk factors
(childhood overweight, LBW, PTB) was about 3% (1040 DALY) (Figure 4). In total, 0.1% of the
total non-communicable disease burden was attributable to maternal smoking in the chained impact
assessment. Congenital anomalies (115 DALY) were associated with the highest disease burden directly
attributable to maternal smoking, followed by asthma (39 DALY).
Disease burden due to diabetes and cardiovascular diseases were the main contributors to the
attributable burden with a total of 18,000 DALY and 12,000 DALY respectively (Figure 5), corresponding
to 550 DALY and 370 DALY indirectly attributable to maternal smoking. The indirect contribution of
maternal smoking to disease burden exceeds the directly attributable disease burden (Figure 5).
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are not available for early markers of disease or non-medical endpoints, such as lower academic 
achievements or generally decreased quality of life. The assessment is further complicated by the 
availability of some health effects, such as high cholesterol levels or markers of metabolic disease as 
risk factors in the GBD database. These risk factors cannot easily be used for the estimation of DOHaD 
attributable disease burden due to potential double-counting of disease burden. Secondly, the 
chained risk model was limited by the availability of exposure-response relationship between 
maternal smoking or intermediate risk factors and later life effects with high evidence for causality. 
A systematic approach is needed to evaluate the evidence for causality and strength of association 
between early exposures and health in later life, which then can be used in a comprehensive risk 
assessment. Thirdly, the burden of disease is estimated in a cross-sectional design. In the risk 
assessment of prenatal and early postnatal exposures the time lag between exposure and outcome is 
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Figure 6. Maternal smoking and risk factor attributable disease burden divided by years lived with
disease (YLD) and years lost due to premature death (YLL); (a) direct impact; (b) direct and indirect
impact of maternal smoking.
4. Discus ion
As the relative rate in prevalence of non-communicable diseases is rising due to bet er control of
infectious diseases and an aging society, the scientific and medical community is aiming to identify
modifiable risk factors in disease etiology, which are ne ded to design efficient strategies for disease
prevention. To date, the established risk factors fail to explain a majority of disease burden. Increasing
understanding of epigenetics and the mixture of internal and external exposures underline the
complexity of is the subtle sub-clinical effects of many exposures throughout
the life course, w ich a a sum affect the susceptibility for disease. Th developmental origin of
health and disease (DOHaD) suggests pre- and early postn tal exposures as r isi for
understanding later life susceptibility. The health risks of developmental exposures are not yet well
understo d for the whole life course. In this work we demonstrated the potential of developmental
exposures to explain disease burden throughout he life course.
We demonstrate that the DOHaD principle can be used to characterize health consequences of
developmental exposures throughout the life course. e estimated the health effects of maternal
smoking, a well characterized prenatal exposure and risk factor, using a chained risk model. The
chained assessment accounts for health effects of risk factors intermediat in he sequential chain from
maternal smoking t chronic diseases: PTB, LBW, and childhood overweight and obesity. How ver,
the risk characterization is limi ed by data gaps. Firstly, the GBD background health ata are no
available for e rly ma kers of disease or non-medical endpoints, such as lower academic achievem nts
or generally decreas d quality of life. The assessment is further complicated by the availability of some
health effects, such as igh chol s erol level or markers of metabolic dise se a risk factors in the GBD
datab se. These risk factors c nnot easily be used for the estimation of DOHaD a tributable disease
burden due to potential double-counting of disease urden. Secondly, the chained risk model was
limited by the availability of exposure-response re tionship b tween maternal moking or interm diat
risk factors and later life effects with high evidence for causality. A systematic approa h is needed to
evalua the evidence for causality and strength of association between early exposures and health in
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later life, which then can be used in a comprehensive risk assessment. Thirdly, the burden of disease is
estimated in a cross-sectional design. In the risk assessment of prenatal and early postnatal exposures
the time lag between exposure and outcome is potentially decades. A lifetable approach, modelling
the changes in exposure level and background burden over the life course, is needed to gain more
detailed insight into the distribution of associated disease burden. In general, the results of this scoping
work to demonstrate the concept must be validated and refined by systematic bottom-up analyses of
exposures, risks and long term disease burden trends.
The health effects quantified in this work is likely to be only the tip of the iceberg. We excluded
studies that reported only at all cancers aggregated (“Any cancer”) due to clear differences in etiology
of cancer types casting doubt on the reliability of such a grouping. However, fairly consistent increases
in risk for certain cancer types of around 20% have been reported for childhood overweight [30],
possibly contributing considerably to the total attributable disease burden. A wide range of health
effects, from sub-clinical metabolic changes to mental and cognitive affecting later life happiness and
productivity, were excluded from the risk model due to a lack of reliable background disease burden
(Table 3). GBD2017 estimates suggest a total disease burden attributable to metabolic risk factors of
about 383,000 DALY in Finland in 2017, accounting for roughly half of the total burden attributable
to risk factors included in the GBD2017 study. High BMI and high fasting plasma glucose level are
the main contributors to metabolic risks with about 160,000 attributable DALY each, followed by
high cholesterol levels (82,000 DALY) [31]. Considering that LBW has been shown to be associated
with metabolic syndrome [32], the estimates of attributable disease burden presented in this work are
likely to underestimate the true disease burden by excluding early stages of diseases as they are only
available as risk factor and not cause in the GBD database. Neonatal preterm birth is included as a
cause for disease burden in the GBD2017 study, accounting for 7026 DALY in Finland in 2017 [33].
This is considerably higher than the roughly 1300 DALY we estimated as attributable to PTB. In the
estimation of PTB disease burden the GBD2017 include infectious diseases and a wide variety of severe
long term effects, such as blindness, cognitive and motor impairments, potentially contributing to the
higher attributable disease burden [34].
Furthermore, our results may underestimate the disease burden because trans-generational health
effects in the offspring of the in utero exposed population are not accounted for. Asthma [35] and
gestational diabetes [36] are examples of the health effects associated with grand-maternal smoking.
Additionally, we did not take increased risk for all natural cause premature mortality into account.
Caution is advised that the BoD estimates presented in this work are order of magnitude estimates
and will change with accumulating data. LBW and PTB are partly overlapping conditions with LBW
(birth weight < 2500 g) being more prevalent in preterm infants than term infants. Thus, the associated
disease burdens may be overlapping.
Int. J. Environ. Res. Public Health 2020, 17, 1472 11 of 17
Table 3. Exemplary outcomes associated with maternal smoking and associated intermediate risk














Pediatric Quality of Life Inventory Index [38]
Academic performance [39]





Wheezing [43,44] [45] [45,46]
Decreased lung function (FEF75, FEV1, FVC) [47] [47,48]
Metabolic
Cortisol secretion [49] [50]
Metabolic syndrome [32] [51]
Total cholesterol [52] [53]
Other
Congenital anomalies [54]
Age at menarche [55]
Bone mineral density [56]
Periodontal disease [57]
* All associations listed here were statistically significant at 95% confidence in the reviewed meta-analyses.
Up to 0.1% of the total non-communicable disease burden was attributable to maternal smoking.
The total share of included early life risk factors was associated with up to 3% of the total burden,
demonstrating the potentially devastating impact on health decades later. Although the chained risk
model is based on an extensive literature review to identify health outcomes of the risk factors, the risk
assessment was constrained by heavy data limitations as pointed out above. Thus we expect the actual
attributable disease burden to be substantially higher.
Roughly 34,000 DALY were attributable to developmental origin in this work. Thus burden of
developmental risk factors is comparable with disease burden attributable to air pollution in Finland.
In 2015 about 35,000 DALY were attributable to particulate matter (PM2.5, PM10), nitrogen dioxide,
and ozone [58]. The health impact of ambient ozone has been estimated to be between 750 and
1500 DALY [2,58], ranging in the same order of magnitude as the total health impact of maternal
smoking (1200 DALY) estimated in this work. Air pollution is recognized as a serious public health
problem with high priority in research and policy making [59]. This work highlights the importance of
the developmental period for overall health for the rest of the life. Providing the best start to a healthy
life requires multidisciplinary efforts to reduce any harmful insults during sensitive developmental
periods by improving awareness of the parents and families of harmful exposures such as smoking
and contaminants in the ambient environment. The identification of unborn babies at risk and the
management of these pregnancies should be public health priority. This includes efforts to educate the
expecting families about risk factors and harmful exposures such as (second hand) tobacco smoking,
unbalanced diet and stress.
While this work is based on estimates for the Finnish population, maternal smoking is a global
public health problem [60]. Recent rates of maternal smoking remain at around 10% in the Nordic
Countries and Australia [61,62] and up to 38% in Ireland [60]. Although population attributable
fractions and background burdens vary between countries, the order of magnitude of the relative
importance of diseases in the total burden in Western countries is comparable. Smoking during
pregnancy and risk factors during early life are likely to contribute to disease burden in a similar
relative order of magnitude as in Finland. Similarly, LBW, PTB, and childhood overweight are
public health concerns globally with high prevalence rates [63–65]. Thus legislative smoking bans,
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as introduced in Finland with the latest revision of the Tobacco act, will considerably improve public
health. Disease burden in active smokers will greatly decrease, but also in prenatally exposed children.
The associated decrease in risk factors for later life disease will have long-term beneficial effect on
chronic disease burden in the population.
4.1. Biological Plausibility
Application of epigenetics and exposome methods are in their infancy in environmental
epidemiology. As there is not sufficient understanding of disease etiology to link maternal smoking
associated epigenetic changes, exposome, and sub-clinical effects to background disease burden,
we propose that epigenetic changes caused by maternal smoking are reflected in the sequential,
intermediate risk factors [16,19,24]. Therefore, a chained risk assessment from maternal smoking
via these mediators to health endpoints is a promising approach, even though there is limited
epidemiological evidence for a direct association between maternal smoking and the health endpoints.
The nested risk model relies on the assumption of causality between the risk factors and
included health outcomes. By including only endpoints identified as statistically significant in well
conducted meta-analyses we hope to ensure a reasonable level of reliability. However, statistical
significance in meta-analyses alone is not sufficient to infer causality, especially with long lag time
between the exposure of concern and health endpoint and considerable potential for confounding [66].
Mechanistic explanations are slowly emerging for the increased susceptibility to diseases later in life,
due to sub-optimal developmental environment. It has been suggested that at least (i) alterations in
gene expression, potentially altering detoxification of xenobiotics, mediated via epigenetic changes;
(ii) changes in neuroendocrine system, including increased levels of glucocorticoids and dysregulated
hypothalamic-adrenal axis; (iii) irreversible changes in organ structure; and (iv) cellular aging are
possible mechanisms explaining an increase of the observed effect [67].
Currently, comprehensive health impact assessment of developmental exposures along the life
course is complicated by the limited availability of birth cohorts followed long-term. Such cohorts are
necessary to better understand the disease etiology with potentially interacting risk factors. Advanced,
careful study design, and sufficient study sizes are essential for causal inference, especially with
potentially decade long latency [66]. Register-based study design can facilitate the needed big study
sizes and it reduces the need to contact study participants for follow-up over long time periods.
Additionally, the majority of epidemiological studies include LBW as in indicator for sub-optimal
in utero development, despite the evidence that general LBW is not a good predictor for future
health. Growth rate, gestational age at birth and body composition and proportions need to be
taken into account to distinguish pathologically small infants from constitutionally small infants [68].
There is already sufficient evidence for differences in etiology and long term consequences of the
so-called symmetrical and asymmetrical growth restricted newborns. Symmetrical growth restriction
is associated with a poorer prognosis, reduced cell number, proportional reduction in all biometrical
indices, and the period of insult is in earlier gestation [69].
4.2. Uncertainties
Health effects were quantified on cross-sectional data for 2017 leading to all health effects of
maternal smoking attributed to background disease burden of the same year, even if the endpoint is
in the elderly and the exposure was theoretically decades ago. Lack of sufficient exposure, risk, and
background health data prevents a life table approach linking exposure rates with the corresponding
outcome decades later. However, over the last 25 years maternal smoking during early pregnancy rates
have been fairly stable around 15% in Finland. Therefore, we do not anticipate that changes in smoking
patterns and other disease risk factors affect the order of magnitude of the burden of disease estimates.
The burden of disease estimates are directly dependent on estimates of exposure and risk. In
this work we employed a priori selection criteria to include endpoints and risk estimates to aim at a
consistent level of evidence. Nevertheless, the used meta-analyses and with that our disease burden
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estimates are subject to uncertainties. For most associations included in this work, causality between
maternal smoking and the outcomes is not proven. Nevertheless, lack of available meta-analysis may
not necessary suggest lack causality, but may only indicate that there are not sufficient number of
studies, yet, to conduct a meta-analysis or conclude on causality. In addition, some meta-analyses may
have been missed in the literature search and review. Meta-analyses themselves are sensitive to bias,
such as publication bias, selection bias and bias in the original studies included in the pooled analyses.
Additionally, uncertainties arise from the low specificity of LBW as endpoints. Potentially, there are
different subgroups of LBW, such as in term or preterm newborns and symmetrically or asymmetrically
growth restricted newborns. Each of these subgroups may be associated with a distinct group of
later life consequences and some may be associated with maternal smoking or nicotine use, while
others are not. Currently, there is limited evidence for clear differences between subgroups and more
studies distinguishing these subgroups are needed, especially focusing on long-term health effects.
Furthermore, there is a considerable overlap in LBW and PTB, i.e., a big fraction of prematurely born
children is born with a birth weight below 2500 g. Published studies do not always clearly distinguish
between the both and attributed long term effects may not be strictly associated with either of them, but
more generally with immaturity at birth. In epidemiological studies the follow up time is limited by the
availability of study populations with sufficient information on prenatal exposures. Epidemiological
studies with a life-long follow up are needed to analyze any possible health consequences, which may
be missed by short follow up or small study population.
Most risk estimates included in this work are reported for specific age groups, which may be
chosen out of convenience and not for scientific reasons. We apply the risk estimates partly for wider
age ranges than originally reported. This may lead to overestimation of the attributable disease burden,
if the association was not valid outside the reported age range. Similarly, there may be a certain degree
of mismatch between endpoints reported in meta-analyses and corresponding background disease
burden endpoints. We do not anticipate that any mismatch would be that substantial, that it would
change the reported attributable burden of disease.
5. Conclusions
The developmental origin of disease approach was shown to be applicable in a chained health
risk assessment. Tentative estimates for the life-long health impacts in of maternal smoking, mediated
via established intermediate risk factors at birth and during childhood, were obtained. Burden of
disease attributable directly to maternal smoking and associated risk factors for disease later in life
was quantified. The contribution of maternal smoking to the burden of disease attributable to the
risk factors was estimated as indirect burden in a chained risk assessment. Maternal smoking was
associated with 24 endpoints and a corresponding disease burden of 1211 DALY. The total disease
burden attributable to preterm birth, low birth weight and childhood overweight and obesity was
33,500 DALY.
Substantial part of the overall burden of disease due to chronic diseases has not yet been associated
with any risk factors. Chained risk analysis based on developmental exposures is one of the most
promising approaches to tackle the unexplained burden. Although the direct health impact of maternal
smoking is small, it is associated with a range of risk factors for non-communicable diseases. Taking
this risk chain into account emphasizes the high susceptibility for disease later in life caused by
developmental exposures. Later in life effects should be considered in comprehensive risk assessment
of exposures in early life.
Developmental origin of disease stresses the importance of a safe and healthy environment
during developmental periods to achieve healthier life. Consolidated efforts are needed to educate
expectant parents about life long consequences of sub-optimal environment during development of
their child. Better understanding of life-long consequences of prenatal and early postnatal exposures is
needed. The existing birth cohorts with detailed information about prenatal and early postnatal life
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did mostly not reach elderly age yet, and therefore epidemiological studies of the DOHaD paradigm
are complicated and need to continue.
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